Insiders' dealing Report of transactions with shares and related securities of NeuroSearch by persons discharging managerial responsibilities and person/companies closely associated with these Pursuant to section 28a of the Danish Act on Securities Trading, NeuroSearch A/S (NEUR.CO) shall make public transactions with shares and related securities of NeuroSearch A/S by persons discharging managerial responsibilities and persons/companies closely associated with these. Name: Torben Skov Reason: Member of the Board Issuer and ID code / ISIN: NeuroSearch A/S / DK0010224666 Transaction: Sale of shares Trading date. 4 December 2007 Market: The OMX Nordic Exchange Copenhagen A/S Number (pcs): 467 Market value (DKK): 148,763 Name: Jørgen Drejer Reason: Executive Vice President, Director of Drug Discovery Issuer and ID code / ISIN: NeuroSearch A/S / DK0010224666 Transaction: Sale of shares Trading date. 4 December 2007 Market: The OMX Nordic Exchange Copenhagen A/S Number (pcs): 2,000 Market value (DKK): 637,100 Name: Finn Eggert Sørensen Reason: Executive Vice President, CBO Issuer and ID code / ISIN: NeuroSearch A/S / DK0010224666 Transaction: Sale of shares Trading date. 4 December 2007 Market: The OMX Nordic Exchange Copenhagen A/S Number (pcs): 2,500 Market value (DKK): 796,375 Name: Peder Velling Reason: Vice President, Head of Patent Department Issuer and ID code / ISIN: NeuroSearch A/S / DK0010224666 Transaction: Sale of shares Trading date. 4 December 2007 Market: The OMX Nordic Exchange Copenhagen A/S Number (pcs): 1,810 Market value (DKK): 576,576 Name: Dorthe Filtenborg Olesen Reason: Vice President, Director of CMC Issuer and ID code / ISIN: NeuroSearch A/S / DK0010224666 Transaction: Sale of shares Trading date. 4 December 2007 Market: The OMX Nordic Exchange Copenhagen A/S Number (pcs): 426 Market value (DKK): 135,702 Name: Jette Møllmann Reason: Vice President, Director of Legal Department Issuer and ID code / ISIN: NeuroSearch A/S / DK0010224666 Transaction: Sale of shares Trading date. 4 December 2007 Market: The OMX Nordic Exchange Copenhagen A/S Number (pcs): 1,544 Market value (DKK): 491,841 Name: Thomas Varming Reason: Vice President, Head of R&D Administration Issuer and ID code / ISIN: NeuroSearch A/S / DK0010224666 Transaction: Sale of shares Trading date. 4 December 2007 Market: The OMX Nordic Exchange Copenhagen A/S Number (pcs): 1,853 Market value (DKK):590,273 Contact person: Anita Milland, Vice President, CFO, telephone: +45 2016 3432 NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on the OMX Nordic Exchange Copenhagen A/S. Our core business covers the development of novel drugs, based on a broad and well-established drug discovery platform focusing on ion channels and CNS disorders. A substantial part of the Company's activities are partner financed through a broad alliance with GlaxoSmithKline (GSK) and collaborations with among others Abbott and Astellas. The drug pipeline comprises 11 clinical (Phase I-III) development programmes: ACR16 in Huntington's disease (Phase III in preparation), tesofensine in obesity (Phase III in preparation), NS2359 in depression (Phase II) and ADHD (Phase II) in partnership with GSK, NS1209 in epilepsy and pain (Phase II), ABT-894 in ADHD (Phase II) and pain (Phase II) in partnership with Abbott, ACR16 in schizophrenia (Phase I) in partnership with Astellas, ACR325 in bipolar disorder and Parkinson's disease (Phase I) and ABT-107 as well as ABT-560 for the treatment of various CNS diseases - both (Phase I) in collaboration with Abbott as well as NSD-644 (Phase I) in collaboration with GSK. In addition, NeuroSearch has a broad portfolio of preclinical drug candidates and holds equity interests in several biotech companies.
Report of transactions with shares and related securities of NeuroSearch by persons discharging managerial responsibilities and person/companies closely related with these
| Source: NTG Nordic Transport Group A/S
Attachments
